Ozempic for weight loss via EU telehealth

Ozempic (semaglutide) is a GLP-1 receptor agonist originally developed for type 2 diabetes that has shown significant effects on weight loss. Accessing it through EU telehealth means you can be assessed, prescribed, and monitored by licensed physicians without attending a clinic in person.

Who needs Ozempic for weight loss

Ozempic is not a first-line weight loss medication for everyone. It is typically considered for adults with a BMI of 30 or higher, or BMI of 27 or higher with weight-related health conditions such as high blood pressure, type 2 diabetes, or cardiovascular disease.

You may be a candidate if you have:

• Struggled with weight loss through diet and exercise alone
• A family history of type 2 diabetes or heart disease
• Difficulty managing hunger or cravings
• Weight-related joint pain, sleep apnoea, or metabolic concerns

However, Ozempic is not suitable if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or if you are pregnant or breastfeeding. A licensed physician must assess your full medical history before prescribing.

How Ozempic works for weight loss

Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone that regulates appetite and blood sugar. When you take Ozempic, it slows gastric emptying (how quickly food leaves your stomach), increases feelings of fullness, and reduces hunger signals to the brain. This combination typically leads to reduced calorie intake without requiring extreme dietary restriction.

The medication is injected subcutaneously (under the skin) once weekly. Most people start on a low dose and increase gradually over 4-5 weeks to minimise side effects and allow the body to adapt. Weight loss typically becomes noticeable after 4-8 weeks, with continued reduction over 6-12 months of consistent use.

Ozempic is not a standalone solution. It works best alongside sustainable dietary changes, regular physical activity, and behavioural support. Many people find that the appetite suppression makes it easier to stick to healthier eating patterns.

What to expect with EU telehealth

When you start Ozempic through a telehealth platform like AETHERA Health, the process follows a structured pathway:

Assessment: You complete a detailed health questionnaire covering your medical history, current medications, weight loss attempts, lifestyle, and any symptoms. This typically takes 10-15 minutes.

Physician review: A licensed EU physician reviews your information, checks your eligibility, and may request additional details or measurements (such as recent blood pressure or blood glucose readings if relevant).

Prescription and supply: If approved, your prescription is issued and sent to a partner pharmacy. Ozempic is delivered to your home, usually within 3-5 working days depending on your location.

Ongoing monitoring: You have scheduled follow-up consultations (typically at 2 weeks, 6 weeks, and 12 weeks) to assess your response, manage any side effects, and adjust your dose if needed. Between appointments, you can message your physician with questions.

Timeline: From initial assessment to receiving your first injection usually takes 5-7 working days. Full treatment cycles are typically 12 weeks minimum, with the option to continue if you are responding well and tolerating the medication.

Cost: Ozempic via telehealth in the EU ranges from EUR 150-250 per month depending on your location and the platform. This usually includes the medication, physician consultations, and follow-up support. Check your local regulations, as some countries may offer partial reimbursement if you meet specific criteria.

Side effects and what to monitor

Common side effects include nausea, vomiting, diarrhoea, and constipation, especially in the first 2-4 weeks. These typically improve as your body adjusts. Drinking plenty of water, eating smaller meals, and avoiding fatty or sugary foods can help.

Rarer but serious side effects include pancreatitis (severe abdominal pain), gallbladder issues, and rapid heart rate. Your physician will screen for risk factors during the initial assessment and monitor you during follow-ups.

If you experience severe abdominal pain, persistent vomiting, or chest pain, stop the medication and contact your physician immediately.

Ozempic for weight loss across the EU

Ozempic is licensed across the EU for type 2 diabetes. Its use for weight loss (off-label) is legal but varies by country in terms of how it is prescribed and reimbursed.

In Portugal, where AETHERA Health is licensed, telehealth prescriptions for weight loss are permitted under physician supervision. The medication is available through licensed pharmacies and is not routinely reimbursed by the national health service (SNS) for weight loss alone, though private prescriptions are widely available.

In other EU countries such as Spain, France, and Germany, similar frameworks apply: telehealth is regulated and permitted, and semaglutide can be prescribed off-label for weight loss by licensed physicians. Reimbursement policies vary; some countries cover it if you have obesity-related comorbidities, while others require private payment.

Always verify the regulations in your specific country, as rules around telehealth prescribing and medication supply can change. AETHERA Health operates within EU regulatory standards and works with licensed physicians in your jurisdiction.

Next step

If you think Ozempic might be right for you, the first step is a confidential assessment with a licensed physician. They will review your health history, discuss your weight loss goals, and determine whether semaglutide is appropriate and safe for you. The process is straightforward, discreet, and takes less than 20 minutes.

Take the weight loss assessment at https://aetherahealth.eu/assessment/weight